Skip to main content

Table 4 Serum Clinical Chemistry Markers

From: Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males

 

300 mg

600 mg

Week

0

1

3

8

11

0

1

3

8

11

Triglyceride (mg/dl)

86.8 ± 29.5

98.5 ± 46.1

105.3 ± 29.5

110.3 ± 58.8

85.9 ± 41.9

117.5 ± 60.2

115.5 ± 50.5

116.6 ± 40.5

110.9 ± 43.4

97.8 ± 36.1

Cholesterol (mg/dl)

177.0 ± 38.2

182.1 ± 26.1

173.9 ± 32.2

175.0 ± 22.6

166.1 ± 20.7

194.6 ± 24.9*

185.1 ± 22.3*

201.1 ± 20.8*

201.6 ± 37.8*

199.5 ± 31.0*

HDL (mg/dL)

50.1 ± 12.5

51.3 ± 10.9

53.6 ± 17.6

49.4 ± 7.9

48.3 ± 8.9

53.0 ± 4.7

53.8 ± 9.8

58.5 ± 11.9

53.9 ± 18.7

57.0 ± 18.3

LDL (mg/dL)

107.9 ± 26.9

112.0 ± 18.8

105.4 ± 23.5

104.4 ± 22.8

100.6 ± 16.8

115.9 ± 21.5*

111.4 ± 21.7*

124.8 ± 22.0*

127.1 ± 33.5*

121.4 ± 25.2*

GGT (U/L)

23.9 ± 5.7

23.8 ± 4.6

23.1 ± 4.8

27.3 ± 7.9

26.0 ± 7.0

32.3 ± 9.6*

33.6 ± 11.2*

33.6 ± 7.8*

38.8 ± 11.8*

36.4 ± 8.3*

LDH (U/L)

127.0 ± 19.4

130.6 ± 23.3

125.4 ± 19.6

114.5 ± 25.8

130.0 ± 33.0

125.5 ± 17.4

128.0 ± 18.0

132.8 ± 23.4

132.1 ± 24.6

140.6 ± 32.6

Uric Acid (g/dl)

6.1 ± 1.7

5.8 ± 1.1

5.7 ± 0.9

5.2 ± 1.0

5.5 ± 1.4

6.1 ± 1.3

6.1 ± 1.6

6.5 ± 1.2

5.7 ± 1.0

5.7 ± 1.3

Glucose mg/dl

94.5 ± 9.4

95.8 ± 10.3

97.6 ± 10.4

94.0 ± 8.2

93.9 ± 9.6

95.1 ± 8.4

94.3 ± 6.5

100.5 ± 6.1

105.1 ± 17.1

89.9 ± 14.8

BUN (mg/dL)

16.9 ± 2.9

19.4 ± 5.0

20.6 ± 4.5

18.5 ± 3.0

19.4 ± 3.6

21.1 ± 7.6*

22.3 ± 5.1*

22.5 ± 3.8*

19.8 ± 3.5*

21.3 ± 2.4*

Creatinine (mg/dl)

1.4 ± 0.1

1.4 ± 0.2

1.4 ± 0.2

1.3 ± 0.2

1.3 ± 0.3

1.4 ± 0.2

1.4 ± 0.2

1.5 ± 0.2

1.5 ± 0.2

1.3 ± 0.3

Calcium (mg/dl)

12.5 ± 1.7

14.2 ± 3.2

14.8 ± 3.0

14.9 ± 2.1

15.2 ± 3.4

15.6 ± 4.4*

16.4 ± 3.4*

14.9 ± 2.8*

13.7 ± 2.6*

17.0 ± 3.0*

Total Protein g/dL

9.8 ± 0.5

9.9 ± 0.4

9.9 ± 0.6

9.8 ± 0.5

9.5 ± 0.4

10.1 ± 0.6*

10.1 ± 0.7*

10.8 ± 0.7*

10.4 ± 0.7*

10.2 ± 0.9*

Albumin g/dL

7.4 ± 0.6

7.7 ± 0.4

7.8 ± 0.6

7.4 ± 0.5

7.3 ± 0.5

7.9 ± 0.9*

8.0 ± 0.9*

8.5 ± 1.0*

8.3 ± 0.9*

8.1 ± 0.9*

Total Bilirubin (mg/dl)

4.7 ± 0.5

4.8 ± 0.4

4.9 ± 0.5

4.6 ± 0.5

4.6 ± 0.3

5.0 ± 0.5

5.1 ± 0.5

5.4 ± 0.6

5.3 ± 0.6

5.1 ± 0.6

ALP (U/L)

0.8 ± 0.3

0.8 ± 0.6

1.0 ± 0.4

0.9 ± 0.5

0.9 ± 0.6

0.6 ± 0.3

0.6 ± 0.2

0.9 ± 0.4

0.8 ± 0.3

0.8 ± 0.2

AST (U/L)

73.9 ± 13.3

76.3 ± 12.1

73.1 ± 12.8

70.5 ± 15.7

64.0 ± 19.9

77.1 ± 21.3

76.1 ± 21.0

79.5 ± 19.4

76.4 ± 19.0

63.1 ± 27.8

ALT (U/L)

24.4 ± 9.6

24.5 ± 9.3

21.3 ± 6.8

18.3 ± 6.6

30.3 ± 25.1

22.6 ± 6.5

27.3 ± 5.5

30.0 ± 11.7

24.5 ± 8.0

26.3 ± 10.0

CK (U/L)

28.6 ± 11.5

25.6 ± 5.5

22.4 ± 7.2

28.4 ± 10.8

27.1 ± 5.5

28.1 ± 14.2

25.0 ± 7.2

23.8 ± 6.7

28.9 ± 15.6

32.6 ± 10.7

  1. * Denotes significant main effects for groups (p < 0.05) indicating that the 600 mg group had higher baselines that persisted throughout the study, and was apparently independent of 6-OXO supplementation.